Eli Lilly and INCY announce positive efficacy data from the late-stage alopecia study of baricitinib in adolescent patients.

Findings in Burns Journal confirm NexoBrid’s superiority over standard of care in pediatric patients with deep thermal ...

Opus Genetics, Inc. announced the dosing of the first pediatric patient in its Phase 1/2 trial for OPGx-LCA5, a gene therapy targeting Leber congenital amaurosis (LCA). Initial results from this ...

The CIDS Phase III was a multicenter, multinational, randomized, controlled, open label study, conducted in pediatric patients with deep partial thickness (DPT) and full thickness (FT) thermal ...

Sydnexis, Inc. ( a pre-commercial stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration ...

About the CIDS Phase III The CIDS Phase III was a multicenter, multinational, randomized, controlled, open label study, conducted in pediatric patients with deep partial thickness (DPT ...

The ACTIVATE-Kids and ACTIVATE-KidsT Phase 3 studies mark Agios’ first pediatric clinical program for a rare hemolytic anemia, providing valuable insights that will help shape the company’s ...

The Kumasi Metropolitan Assembly (KMA) has launched the second phase of the City Cancer Challenge, introducing four ...

Dr Vivek Verma, Associate Director-Surgical Oncology, Max Super Speciality Hospital Patparganj highlights that pediatric ...

MediWound (MDWD) announced the publication of its Phase III Children Innovative Debridement Study in Burns, the peer-reviewed Journal of the ...

Rosalinda, from Mananara in northern Madagascar, received free surgery on Monday, March 10th on board the Africa Mercy® ...